Several anti-cancer drugs have been identified: (1) Ponatinib, a BCR-ABL tyrosine kinase inhibitor that is used for patients with chronic myeloid leukemia (CML), has great potential to block necroptosis [20,21]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.